HDAC9 and cancer: The unbiased screening for anti-cancer compounds, which in combination with 177Lu-lilotomab satetraxetan synergistically impair proliferation of these cell lines identified three major classes of compounds that may be utilizable to overcome RIT-resistance: topoisomerase inhibitors, HDAC inhibitors, and inhibitors of mitotic cell cycle kinases.